Why Alnylam Pharmaceuticals Stock Slipped Today
Key Points
The biotech released its final set of figures for 2025.
It had a mixed quarter, despite the recent success of a popular product.
- 10 stocks we like better than Alnylam Pharmaceuticals ›
Investors weren't in a very forgiving mood with commercial-stage biotech Alnylam Pharmaceuticals (NASDAQ: ALNY). After the company reported its latest set of quarterly results, those folks showed their displeasure by trading the stock down by more than 4% that trading session.
Amvuttra powers revenue growth
Alnylam took the wraps off its fourth-quarter and full-year 2025 results before market open. These revealed that the company's revenue nearly doubled on a year-over-year basis, landing at just under $1.1 billion.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
Net income not in accordance with generally accepted accounting principles (GAAP) ballooned over that one-year stretch. It was nearly $169.8 million, or $1.25 per share, against the year-ago profit of slightly over $8 million.
With those numbers, Alnylam edged past the $1.19 per share consensus analyst estimate for non-GAAP (adjusted) profitability. On the other hand, it missed the pundits' $1.15 billion revenue forecast.
The company's key top-line driver was Amvuttra, the net sales of which were responsible for the bulk (83%) of its net product revenue for the period.
In March 2025, Amvuttra -- an RNAi medication that was first approved by the Food and Drug Administration (FDA) in 2022 -- was given the nod by the regulator for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This is a disorder in which protein deposits can lead to a thickening of the heart.
Victim of success
For the entirety of 2026, Alnylam is guiding for total revenue of $5.3 billion to $5.8 billion; the analyst consensus of $5.55 billion falls within this range. It did not provide a net income forecast.
Alnylam is enjoying robust sales with Amvuttra's new(ish) indication, so I feel that much of the investor reaction was due to extremely optimistic expectations. I'd be more bullish on the stock, as take-up has been quick, and the product is clearly resonating with clinicians and patients. I feel it has plenty of room to run at this stage.
Should you buy stock in Alnylam Pharmaceuticals right now?
Before you buy stock in Alnylam Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alnylam Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $429,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,165,045!*
Now, it’s worth noting Stock Advisor’s total average return is 913% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 12, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.
Recommended Articles
